Bella Kushnir, MD
Internal Medicine · Brooklyn, NYNPI 1770743320
Payments from drug & device makers
Across 401 payments — averaging $75.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$23K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- GSK$868
- Amgen$756
- Novartis$414
- Merck$388
- plus $4K from 26 others
What the payments were for
- Speaking & faculty fees$21,30071%
- Travel & lodging$20%
- Food & beverage$8,86829%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 81 | $22,965 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 79 | $1,230 |
| GSK | 37 | $868 |
| Amgen(2 entities) | 24 | $756 |
| Novartis | 19 | $414 |
| Merck | 16 | $388 |
| Pfizer | 15 | $373 |
| Amarin Pharma, Inc. | 13 | $340 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $337 |
| Lilly USA, LLC | 12 | $314 |
| Ardelyx, Inc. | 9 | $289 |
| Novo Nordisk | 14 | $277 |
| Johnson & Johnson | 4 | $210 |
| E.r. Squibb & Sons, L.L.C. | 5 | $187 |
| Aimmune Therapeutics, Inc. | 2 | $150 |
| Nestle Healthcare Nutrition Inc. | 7 | $146 |
| Boehringer Ingelheim | 8 | $145 |
| Endo Pharmaceuticals Inc. | 6 | $126 |
| Shield Therapeutics Inc | 5 | $114 |
| Axsome Therapeutics, Inc. | 3 | $71 |
| Astellas Pharma US Inc | 3 | $66 |
| Idorsia Pharmaceuticals US Inc | 4 | $64 |
| Corcept Therapeutics | 2 | $50 |
| Vistapharm, Inc. | 3 | $50 |
| Myriad Genetic Laboratories, Inc. | 1 | $49 |
| Exact Sciences | 2 | $41 |
| Arbor Pharmaceuticals, Inc. | 2 | $40 |
| AstraZeneca | 2 | $38 |
| Intra-sana Laboratories | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Glycomark, Inc. | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,182 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 104 | $267,111 |
| VascepaIcosapent Ethyl | 354 | $151,252 |
| ZenpepLipase/Protease/Amylase | 40 | $124,154 |
| EliquisApixaban | 141 | $116,278 |
| LinzessLinaclotide | 155 | $112,669 |
| JardianceEmpagliflozin | 125 | $111,259 |
| RybelsusSemaglutide | 83 | $93,366 |
| MounjaroTirzepatide | 85 | $92,173 |
| Diclofenac Sodium | 305 | $81,972 |
| ProliaDenosumab | 47 | $73,843 |
| JanumetSitagliptin Phos/Metformin Hcl | 57 | $71,579 |
| OzempicSemaglutide | 45 | $60,668 |
| Dihydroergotamine Mesylate | 38 | $51,541 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $47,043 |
| TradjentaLinagliptin | 72 | $47,001 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Namzaric, Synthroid | $22,965 | $401,745424 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Synjardy | $145 | $209,522291 claims |
| Novo NordiskRybelsus, Ozempic | $277 | $154,034128 claims |
| Lilly USA, LLCMounjaro, Trulicity | $314 | $133,222112 claims |
| Aimmune Therapeutics, Inc.Zenpep | $150 | $124,15440 claims |
| PfizerEliquis | $373 | $116,278141 claims |
| MerckJanumet, Januvia | $388 | $102,362104 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $868 | $76,788126 claims |
| AmgenProlia | $756 | $73,84347 claims |
| Astellas Pharma US IncMyrbetriq | $66 | $26,89448 claims |
| Johnson & JohnsonXarelto | $210 | $25,56726 claims |
| NovartisEntresto | $414 | $20,68819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Brooklyn
- Bruce BergerBrooklyn$3.4M
- Nelly CohenBrooklyn$2.8M
- Jorge SerjeBrooklyn$1.3M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.